Cue Biopharma, Inc. Operating Income Loss

• Cue Biopharma, Inc. showed an increase of +36.0% in Operating Income Loss from 2024 to 2025.
• This data is from Cue Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
• XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 9 years of available data (2017 to 2025), Cue Biopharma, Inc.'s Operating Income Loss has declined by 14.3%.
• Historical annual values: Fiscal year 2025: -$26.55 million | Fiscal year 2024: -$41.50 million | Fiscal year 2023: -$52.15 million | Fiscal year 2022: -$53.23 million | Fiscal year 2021: -$43.71 million | Fiscal year 2020: -$45.04 million | Fiscal year 2019: -$36.77 million | Fiscal year 2018: -$38.70 million | Fiscal year 2017: -$23.23 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026